EuroSIDA

Project Summary 

EuroSIDA is a prospective observational cohort study that was initiated in 1994 to follow the long-term clinical prognosis for the general population of HIV-infected individuals in Europe and to assess the impact of antiretroviral drug treatment on their long-term prognosis.

To date almost 23000 individuals have been followed in 100 collaborating clinics across 35 countries covering all European regions, Israel and Argentina. EuroSIDA aims to study the long-term virological, immunological and clinical outcomes and to monitor temporal changes and regional differences across Europe.  EuroSIDA has investigated co-infection with Hepatitis C virus and clinical events including liver, renal and cardiovascular disease and non-AIDS defining cancers.

EuroSIDA was one of the cohorts to found The International Cohort Consortium of Infectious Disease (RESPOND) cohort consortium on infectious diseases in 2017.

Key Project Information

Dates: 01/01/1994 - (ongoing)

Status: Current

UCL lead/Principal Investigator: Professor Amanda Mocroft

Partners: CHIP – Centre of Excellence for Health, Immunity and Infections, University of Copenhagen, Denmark

Location: Europe, Israel, Argentina

Funding: EuroSIDA has received funding from ViiV Healthcare LLC, Janssen Scientific Affairs, Janssen R&D, Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp, Gilead Sciences and the European Union’s Seventh Framework Programme for research, technological development and demonstration under EuroCoord grant agreement n˚ 260694. The participation of centres from Switzerland has been supported by The Swiss National Science Foundation (Grant 148522).The study is also supported by a grant [grant number DNRF126] from the Danish National Research Foundation and by the International Cohort Consortium of Infectious Disease (RESPOND)

Website: https://chip.dk/Studies/EuroSIDA/About